On February 12, 2024, Metagenomi conducted its initial public offering ("IPO"), selling approximately 6.25 million shares at $15 per share. On May 1, 2024, less than two months after the IPO, Metagenomi announced that it and Moderna had "mutually agreed to terminate their collaboration." Click here to participate in the action. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com NEW YORK, July 18, 202 ...

Exhibit 99.1 Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results Emeryville, CA, May 14, 2024 - Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics- derived gene editing toolbox, today reported financial results and business updates for the first quarter ended March 31, 2024. "Our continued execution in the first quarter of 2024 furthers our m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41949 Metagenomi, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 81-3909017 | | --- | --- | | (State or ...

Exhibit 99.1 Metagenomi Reports Business Updates and Full Year 2023 Financial Results Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of capability demonstrated with CRISPR-associated transposase (CAST) system being developed to enable >10,000 base pair, targeted genomic integrations Ultra-small base editing systems (SMART) are the smallest nickase-based system ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41949 Metagenomi, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81- 3909017 (State or other jurisdiction of in ...